Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Haemonetics (HAE) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Haemonetics (HAE) over the last 17 years, with Q4 2025 value amounting to -$7.4 million.

  • Haemonetics' Non Operating Income rose 1855.79% to -$7.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$23.9 million, marking a year-over-year decrease of 5263.12%. This contributed to the annual value of -$9.7 million for FY2025, which is 2513.44% up from last year.
  • As of Q4 2025, Haemonetics' Non Operating Income stood at -$7.4 million, which was up 1855.79% from -$7.2 million recorded in Q3 2025.
  • Over the past 5 years, Haemonetics' Non Operating Income peaked at $7.0 million during Q2 2024, and registered a low of -$9.1 million during Q4 2024.
  • For the 5-year period, Haemonetics' Non Operating Income averaged around -$4.2 million, with its median value being -$4.5 million (2021).
  • Data for Haemonetics' Non Operating Income shows a peak YoY increase of 43624.94% (in 2024) and a maximum YoY decrease of 36752.18% (in 2024) over the last 5 years.
  • Over the past 5 years, Haemonetics' Non Operating Income (Quarter) stood at -$4.6 million in 2021, then skyrocketed by 77.01% to -$1.1 million in 2022, then crashed by 84.74% to -$1.9 million in 2023, then crashed by 367.52% to -$9.1 million in 2024, then increased by 18.56% to -$7.4 million in 2025.
  • Its Non Operating Income was -$7.4 million in Q4 2025, compared to -$7.2 million in Q3 2025 and -$8.7 million in Q2 2025.